Heart failure & cardiomyopathiesCohort study
Metabolic Dysfunction-Associated Steatotic Liver Disease is Associated with Increased Risks of Heart Failure
- Retrospective cohort study
- propensity-score matched
- multivariable adjustment
Authors' conclusion
In patients with SLD, those with MASLD show a higher risk of HF, specifically HFpEF.
Study context
- Population
- Patients with steatotic liver disease (SLD) without a history of heart failure (HF), 2006–202171% MASLD
- Participants
- 26,676 patients
- Exposure
- MASLD vs non-MASLD
- Outcome
- New development of HF, sub-classified by echocardiography
- Follow-up
- Median 6 years
Main finding
Incident HF
Subdistribution hazard ratio
2.59
95% CI 1.84–3.64
MASLD vs non-MASLD
SHR 2.59 (95% CI 1.84–3.64)
As reported in the abstract
- Patients developing HF (overall)
- 429 (1.61%)
- HF that was HF with preserved ejection fraction (HFpEF)
- 76%
Observational data: associations, not effects.
Further findings
| Outcome | SHR (95% CI) | |
|---|---|---|
| HF risk per additional cardiometabolic risk factor · dose-dependent | 1.12 (1.04–1.22) | |
| HF-related hospitalisation | 2.30 (1.31–4.04) | |
| HFpEF | 1.91 (1.27–2.86) | |
| 0.20.5125Subdistribution hazard ratio (log scale) |
HF (propensity score-matched cohorts)
- MASLD associated with higher risk of HF
- 2.52-fold
- matched cohort
Original publication
Metabolic Dysfunction-Associated Steatotic Liver Disease is Associated with Increased Risks of Heart Failure. Eur J Heart Fail. Published 8 January 2025. doi:10.1002/ejhf.3567
Summarised from the published abstract; every number is checked against it